At the end of last year, EUROIMMUN and Xpedite Diagnostics announced the start of a strategic partnership. Now the time has come: EUROArray SwiftX-traction is a rapid extraction procedure enabling the isolation of pathogen DNA for further analysis using EUROIMMUN’s EUROArrays. It has been especially developed for EUROIMMUN and is now approved worldwide for diagnostic […]
Autoantibodies targeting the protein RGS8 (regulator of G-protein signaling 8) are associated with a particular subtype of Hodgkin’s lymphoma, as described in a recently published study performed in a collaboration between EUROIMMUN and research institutes in France, Spain and USA. The novel autoantibodies are suggested to be of at least intermediate risk for paraneoplastic neurological
Currently, many patients are presenting themselves at the doctor’s with symptoms of the common cold, such as cough, runny nose, headache and fever. These symptoms are typical of this time of year and can be caused by a number of different pathogens. In many cases, only differential diagnostics can help to identify the pathogen and
On 14th November 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency announced their positive opinion on the marketing authorisation of lecanemab (monoclonal anti-beta-amyloid antibody; trade name: Leqembi from Eisai and Biogen) in the European Union for the treatment of early Alzheimer’s disease in Europe. In 2023, the drug
EUROIMMUN chemiluminescence immunoassays (ChLIA) for Alzheimer’s disease (AD) biomarkers provide reliable analytical and clinical performance, as demonstrated in two newly published studies performed in a collaboration between researchers at EUROIMMUN and the Memory Clinic of the University Hospital Magdeburg, Germany. Measurement of the four core biomarkers beta-amyloid (Aβ) 1-40, Aβ1-42, total tau and tau phosphorylated
